34272-65-6

Usage

Uses

Used in Pharmaceutical Research and Development:
(2,4-DIMETHYL-THIAZOL-5-YL)-ACETIC ACID is used as a building block in organic synthesis for its potential biological activity, contributing to the development of new drugs and serving as a key intermediate in pharmaceutical production.
Used in Agrochemical and Veterinary Product Manufacturing:
(2,4-DIMETHYL-THIAZOL-5-YL)-ACETIC ACID is utilized as a key component in the manufacture of agrochemical and veterinary products, highlighting its versatility and importance in different industries.
Used in Disease Treatment Research:
(2,4-DIMETHYL-THIAZOL-5-YL)-ACETIC ACID is being studied for its potential use in the treatment of various diseases, indicating its promising role in medical and therapeutic applications.

InChI:InChI=1/C7H9NO2S/c1-4-6(3-7(9)10)11-5(2)8-4/h3H2,1-2H3,(H,9,10)

Upstream product

• 405921-41-7 ethyl 2-(2,4-dimethylthiazol-5-yl)acetate 
• 62-55-5 thioacetamide 
• 62557-43-1 3-bromolevulinic acid 
• 64-17-5 ethanol 
• 123-76-2 levulinic acid 

Downstream Products

• 13623-11-5 2,4,5-trimethylthiazole 
• 405921-41-7 ethyl 2-(2,4-dimethylthiazol-5-yl)acetate 
• 142437-68-1 2-(2,4-dimethyl-thiazol-5-yl)-ethylamine 
• 50382-35-9 (2,4-dimethyl-thiazol-5-yl)-acetonitrile 
• 61928-55-0 2-(2,4-dimethyl-thiazol-5-yl)-acetamide 
• 1444398-38-2 C₂₄H₂₉N₇O₂S 
• 59865-88-2 2-(2,4-dimethyl-thiazol-5-yl)-N-phenyl-acetamide 

Relevant academic research and scientific papers

Overall synthesis of GSK356278: Quick delivery of a PDE4 inhibitor using a fit-for-purpose approach

The family of phosphodiesterase (PDE) enzymes hydrolyse cyclic nucleotides, cAMP and cGMP, leading to their inactivation as intracellular second messengers. Inhibition of these enzymes leads to an elevation of levels of cyclic nucleotides in the cell and prolongs their action on downstream signaling pathways. PDE4, of which there are four subtypes, is widely expressed throughout the brain but is also abundant in the periphery in inflammatory and immune cells, in the gastrointestinal tract, and in cardiac myocytes. GSK356278 1 is a potent, selective, and competitive inhibitor of PDE4 enzymes currently under investigation for the treatment of CNS disorders. The initial synthetic route developed by Medicinal Chemistry Department, used several hazardous and/or expensive reagents and harsh conditions and gave relatively low yields. By targeted process of research and development plus application of analytical techniques to identify byproduct and extensive route scouting, a novel synthetic route for 1 has been developed. This contribution reports the optimisation of the chemical synthesis of 1 to develop a large-scale process suitable for its synthesis.